
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc. is advancing its development in the oncology space with a significant focus on CNS cancers, notably through its candidate rhenium (186Re) obisbemeda. Positive developments include the receipt of an $18 million grant for studying leptomeningeal metastases and strategic expansions of its CNSide Diagnostics platform, which have bolstered operational capabilities and broadened market access. These advancements, combined with anticipated milestones and data releases expected in 2025/26, support a favorable long-term outlook for the company’s stock, as they enhance its commercial potential and operational scalability.
Bears say
Plus Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily revolving around the potential failure of its product candidates, including rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, the company may struggle to secure regulatory approval for commercial sale, as well as suitable reimbursement, which could hinder its revenue generation prospects. Furthermore, increased competition in the oncology market and shifting macroeconomic conditions could further exacerbate the challenges Plus Therapeutics faces in achieving its financial objectives.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares